These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 12216098)

  • 1. Phase I study of fotemustine in pediatric patients with refractory brain tumors.
    Hargrave DR; Bouffet E; Gammon J; Tariq N; Grant RM; Baruchel S
    Cancer; 2002 Sep; 95(6):1294-301. PubMed ID: 12216098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fotemustine in the treatment of brain primary tumors and metastases.
    Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
    Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
    Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
    J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II evaluation of topotecan for pediatric central nervous system tumors.
    Blaney SM; Phillips PC; Packer RJ; Heideman RL; Berg SL; Adamson PC; Allen JC; Sallan SE; Jakacki RI; Lange BJ; Reaman GH; Horowitz ME; Poplack DG; Balis FM
    Cancer; 1996 Aug; 78(3):527-31. PubMed ID: 8697400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
    Vassal G; Boland I; Terrier-Lacombe MJ; Watson AJ; Margison GP; Vénuat AM; Morizet J; Parker F; Lacroix C; Lellouch-Tubiana A; Pierre-Kahn A; Poullain MG; Gouyette A
    Clin Cancer Res; 1998 Feb; 4(2):463-8. PubMed ID: 9516937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study.
    Beauchesne PD; Taillandier L; Bernier V; Carnin C
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):171-5. PubMed ID: 19352662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study.
    Fouladi M; Blaney SM; Poussaint TY; Freeman BB; McLendon R; Fuller C; Adesina AM; Hancock ML; Danks MK; Stewart C; Boyett JM; Gajjar A
    Cancer; 2006 Nov; 107(9):2291-7. PubMed ID: 17019740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Logistic regression model of fotemustine toxicity combining independent phase II studies.
    Raymond E; Haon C; Boaziz C; Coste M
    Cancer; 1996 Nov; 78(9):1980-7. PubMed ID: 8909320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule.
    Khayat D; Lokiec F; Bizzari JP; Weil M; Meeus L; Sellami M; Rouesse J; Banzet P; Jacquillat C
    Cancer Res; 1987 Dec; 47(24 Pt 1):6782-5. PubMed ID: 3677107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fotemustine: a pilot phase II trial in sarcoma of the soft tissues].
    Spielmann M; Berille J; Khayat D; Bizzari JP; Jacquillat C; Tursz T
    Bull Cancer; 1991; 78(5):453-6. PubMed ID: 1878607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.
    Hawkins DS; Bradfield S; Whitlock JA; Krailo M; Franklin J; Blaney SM; Adamson PC; Reaman G
    Pediatr Blood Cancer; 2006 Nov; 47(6):790-4. PubMed ID: 16435380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fotemustine (Muphoran) in 22 patients with relapses of high-grade cerebral gliomas].
    Malhaire JP; Lucas B; Simon H; Person H; Dam-Hieu P; Labat JP
    Bull Cancer; 1999 Mar; 86(3):289-94. PubMed ID: 10210763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors.
    Kellie SJ; Koopmans P; Earl J; Nath C; Roebuck D; Uges DR; De Graaf SS
    Cancer; 2004 Jun; 100(12):2637-43. PubMed ID: 15197807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study.
    Gururangan S; Turner CD; Stewart CF; O'Shaughnessy M; Kocak M; Poussaint TY; Phillips PC; Goldman S; Packer R; Pollack IF; Blaney SM; Karsten V; Gerson SL; Boyett JM; Friedman HS; Kun LE
    Clin Cancer Res; 2008 Feb; 14(4):1124-30. PubMed ID: 18281546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001).
    Hartmann JT; Mayer F; Schleicher J; Horger M; Huober J; Meisinger I; Pintoffl J; Käfer G; Kanz L; Grünwald V;
    Cancer; 2007 Aug; 110(4):861-6. PubMed ID: 17599772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation.
    Fabi A; Metro G; Russillo M; Vidiri A; Carapella CM; Maschio M; Cognetti F; Jandolo B; Mirri MA; Sperduti I; Telera S; Carosi M; Pace A
    BMC Cancer; 2009 Mar; 9():101. PubMed ID: 19335893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.
    Wagner S; Erdlenbruch B; Längler A; Gnekow A; Kühl J; Albani M; Völpel S; Bucsky P; Emser A; Peters O; Wolff JE
    Cancer; 2004 Apr; 100(8):1750-7. PubMed ID: 15073866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose fotemustine as second-line chemotherapy for recurrent glioblastoma multiforme.
    De Felice F; Bulzonetti N; Musio D; D'Elia A; Salvati M; Tombolini V
    Anticancer Res; 2013 Sep; 33(9):4013-6. PubMed ID: 24023343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte 06-alkylguanine-DNA alkyltransferase activity.
    Boiardi A; Silvani A; Ciusani E; Watson A; Margison G; Berger E; Lucas C; Giroux B
    J Neurooncol; 2001 Apr; 52(2):149-56. PubMed ID: 11508814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.
    Bagatell R; Gore L; Egorin MJ; Ho R; Heller G; Boucher N; Zuhowski EG; Whitlock JA; Hunger SP; Narendran A; Katzenstein HM; Arceci RJ; Boklan J; Herzog CE; Whitesell L; Ivy SP; Trippett TM
    Clin Cancer Res; 2007 Mar; 13(6):1783-8. PubMed ID: 17363533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.